Ginkgo Bioworks Holdings Inc (DNA)

[Talc Moan]

Oh look another Filing. More dilution. 148,914,967 additional shares of the Company’s Class A common stock, $0.0001 par value per share (the “Class A Common Stock”) and 148,914,967 additional shares of the Company’s Class B common stock

[Talc Moan]

DNA Ginkgo Is a share selling Scam that ARKK keeps averaging down. They will reverse split or be delisted once under a buck and sent to otc markets.

[enthalpy]

Well this company ginkgo is listed as having 74 million at risk uninsured at silicon valley bank. Bankruptcy?

https://www.forbes.com/sites/tylerroush/2023/03/11/these-companies-roku-lendingclub-roblox-and-more-held-major-funds-in-silicon-valley-bank-when-it-crashed/?sh=18f02fad3d6e

[Talc Moan]

100%! And they did the usual pinky 10k filing extension plus they have exposure to SIVB. Complete shit show.

[Porterhouse10]

Oh yeah, it's crazy, with a 1.94 Bill OS it's like a Pinky and maybe headed there!

[Talc Moan]

Wasn’t making fun of the trade just the drop in Price and Cathie Wood keeps buying this dilution Machine. GLTY as well.

[Porterhouse10]

The trade was already made, GLTY

[Talc Moan]

$2.60 lolololololol this is a dilution mean and in a race to sub $1.00 vs bbby

[Talc Moan]

Reverse Split imo announced once DNA falls below $1.00 threshold.

[buyittradeit]

Wonder if the Senate will grill Powell on printing paper and how will that work out for the market if they do.

[trade2brich]

ARK just bought about 2.4 million shares!!!! Yeah, I feel good about this.

[lettruthringout]

Aircraft Wastewater Surveillance for Detection of SARS-CoV-2 Variants

As SARS-CoV-2 testing declines worldwide, surveillance of international travelers for SARS-CoV-2 enables detection of emerging variants and fills gaps in global genomic surveillance (1). Because SARS-CoV-2 can be detected in feces and urine of some infected persons (2), wastewater surveillance in airports and on aircraft has been proposed by the global public health community† as a low-cost mechanism to monitor SARS-CoV-2 variants entering the United States. Sampling wastewater directly from aircraft can be used to link SARS-CoV-2 lineage data with flight origin countries without active engagement of travelers (3).

During August 1–September 9, 2022, the biotech company Ginkgo Bioworks, in collaboration with CDC, evaluated the feasibility of SARS-CoV-2 variant detection in aircraft wastewater from incoming international flights. Aircraft wastewater samples were collected from selected flights from the United Kingdom, Netherlands, and France arriving at John F. Kennedy International Airport in New York City. Wastewater (approximately 0.25 gal [1 L]) was collected from each plane during normal maintenance using a device that attaches to the lavatory service panel port and the lavatory service truck hose.

After concentration with affinity-capture magnetic nanoparticles (4), wastewater samples were tested for SARS-CoV-2 by reverse transcription–polymerase chain reaction (RT-PCR).§ Samples with cycle thresholds <40 underwent whole genome sequencing using ARTIC (version 4.1; ARTIC Network) primers.¶ Multiple lineages within samples were identified using Freyja, a tool for deconvolution of complex samples.** Sequences meeting quality control criteria (e.g., >70% genome coverage)†† were assigned to sublineages using Pangolin (version 4.1.3)§§ and reported to the airline, public SARS-CoV-2 genomic data repositories, and the CDC National Wastewater Surveillance System. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.¶¶

During August 1–September 9, 2022, one sample was collected from each of 88 flights (Figure). Sample collection added approximately 3 minutes to normal aircraft maintenance times. Eighty samples were tested for SARS-CoV-2.*** Overall, 65 samples (81%) were positive; the percentage that were positive was similar among the three flight origin countries sampled (Netherlands: 81% [22 of 27]; France: 81% [22 of 27]; and United Kingdom: 81% [21 of 26]). Twenty-seven SARS-CoV-2 genomes were detected in 25 wastewater samples; sequencing quality control criteria were not met for the remaining 40 positive samples. All identified genomes were Omicron sublineages (United Kingdom: 12 BA.5 and one BA.4.6; France: eight BA.5; and Netherlands: five BA.5 and one BA.2.75). In each of 23 samples, single SARS-CoV-2 genomes were identified and assigned to the BA.5 (21), BA.4.6 (one), and BA.2.75 (one) sublineages. In each of two additional samples, two distinct SARS-CoV-2 genomes were identified and assigned to different BA.5 sublineages (Figure). The SARS-CoV-2 genomes identified in aircraft lavatory wastewater were consistent with Western European sequences uploaded to the Global Initiative on Sharing Avian Influenza Data (GISAID) at the time (approximately 90% BA.5).†††

This investigation demonstrated the feasibility of aircraft wastewater surveillance as a low-resource approach compared with individual testing to monitor SARS-CoV-2 variants without direct traveler involvement or disruption to airport operations. Limitations include dependence on lavatory use during the flight, which correlates with flight duration (5); inability to distinguish travelers with connecting flight itineraries, which lessens precision when ascertaining variant origin; and potential carryover of residual SARS-CoV-2 RNA between flights yielding viral detections unrelated to travelers on the flight. Stringent genome coverage thresholds might reduce the likelihood of carryover variant identification on subsequent flights.

In addition to routinely monitoring variants entering the United States, this modality can be surged based on global public health needs (e.g., outbreaks or mass gatherings in settings with limited SARS-CoV-2 variant surveillance). In combination with traveler-based surveillance (1), aircraft wastewater monitoring can provide a complementary early warning system for the detection of SARS-CoV-2 variants and other pathogens of public health concern.

https://www.investorvillage.com/smbd.asp?mb=20048&mn=22&pt=msg&mid=23927866

[lettruthringout]

Ginkgo snags DARPA contract

DARPA RPM Aims to Speed-Up Production of On-Demand Protein-Based Therapeutics
Agency names performers for Reimagining Protein Manufacturing program
[e-mail]
2/15/2023

Reimaging Protein Manufacturing (RPM)
Department of Defense (DoD) access to critical protein-based therapeutics is limited by the slow pace and substantial costs associated with current protein production methods. The goal of the DARPA Reimaging Protein Manufacturing (RPM) program is to develop tools for distributed, on-demand manufacturing of protein-based drugs, such as antibodies or vaccines, or the proteins required to make them. DARPA has selected performer teams that aim to demonstrate immediate production -- initiated within 24 hours -- of protein products with yields in excess of 500 units per week with correct protein modifications.

“The current process for producing protein-based therapeutics requires more than a year to establish, while still requiring purification and significant infrastructure,” noted RPM program manager, Dr. Michael Feasel. “RPM aims to initiate protein production within 24 hours, eliminating this long lead time. Fast, on-demand distributed manufacturing could make key proteins on a DoD-relevant timeline in operational environments.”

The 50-month RPM program will address two technical areas. Technical Area 1, Production Yield and Time, focuses on protein synthesis technologies for near-immediate manufacture of proteins at high yields. Technical Area 2, Post-Translational Modifications, seeks novel approaches to make necessary modifications to proteins after production, in a controlled manner to ensure that the final product is bioactive and of high quality.

DARPA selected the following research teams, which are pursuing a variety of approaches to meet the challenges of RPM: Ginkgo Bioworks, Inc., Leidos Inc., and Northwestern University.

“In biology, cellular protein production follows a central dogma: DNA makes RNA and RNA makes protein. Cells do this efficiently, but when you engineer cells to make a protein of your choice, the protein production process is much more time consuming,” Feasel said. “RPM aims to remove the cells from the process using cell-free protein synthesis technologies to decrease time to production, increase yield of production, and perform the correct protein modifications.”

DARPA will utilize independent validation and verification partners throughout the program to assess the function, stability, and composition of the proteins produced through a series of field-recognized analytical techniques.


https://www.darpa.mil/news-events/2023-02-15

[lettruthringout]

Institutions added in 4th quarter

https://www.investorvillage.com/smbd.asp?mb=20048&mn=17&pt=msg&mid=23906518

[Porterhouse10]

Boom!

[trade2brich]

Buying consistently every week.

[Porterhouse10]

Did ya get any $DNA 200MA is $2.60

[lettruthringout]

National Security Commission on Emerging Biotechnology

Lawmakers round out membership of new emerging biotech commission
By Briana Reilly / December 30, 2022 at 4:05 PM

Legislative defense leaders today announced the full slate of members tapped to serve on a recently established commission tasked with making recommendations on the use of emerging biotechnology and biomanufacturing in the military.

Though the congressional defense committee’s top Democrats and Republicans had previously announced their joint selection of eight appointees back in March, it wasn’t until nine months later that the final four commissioner slots -- and the panel’s chair and vice chair -- were unveiled.

The 12-member body was created in the Fiscal Year 2022 National Defense Authorization Act, which called on the panel to review advances in emerging biotech, biomanufacturing and related areas while keeping in mind “the methods, means, and investments necessary to advance and secure” development of those technologies.

Helming the so-called National Security Commission on Emerging Biotechnology is Jason Kelly, the co-founder and CEO of synthetic biology company Ginkgo Bioworks, while Michelle Rozo will take the No. 2 role, according to a press release from the House and Senate Armed Services committees. Rozo, whose membership was first announced today, most recently served as the National Security Council’s director for technology and national security.

Under the FY-22 NDAA, eight of the commission’s members were to be selected by the heads of the armed services committees, while the remaining four positions were to be filled by the House speaker and minority leader, as well as the Senate majority and minority leaders. The four members newly announced today, including Rozo, are: Eric Schmidt, the former Google CEO and first chairman of the Defense Innovation Board; Angela Belcher, who helms MIT’s Department of Biological Engineering; and Dawn Meyerriecks, who most recently served as the deputy director of the CIA for science and technology.

The other members, all of whom were previously named, include four lawmakers: Reps. Stephanie Bice (R-OK) and Ro Khanna (D-CA), as well as Sens. Alex Padilla (D-CA) and Todd Young (R-IN). Also serving on the panel are Paul Arcangeli, an 18-year veteran House Armed Services Committee staffer who retired in spring 2022; Dov Zakheim, a former Defense Department chief financial officer and under secretary of defense; and Alexander Titus, a product strategy and operations lead at Google Research who previously served as the office of the under secretary of defense for research and development’s assistant director for biotechnology.

The law’s text directs the commission to consider a number of things while conducting that review, ranging from ways to grow the nation’s bioeconomy and commercial industry through the development of biotech-enabled capabilities to avenues to establish international standards for biotech, biomanufacturing and digital biosecurity.

Members are expected to submit their initial findings to the congressional defense committees within a year of the commission’s establishment, with a final report due within a two-year timeframe, per the language.

[lettruthringout]

Will large government contracts ensue? Which additional countries?

CDC figuring out 'logistical and legal' aspects of testing airplane wastewater for coronavirus variants, source says
Posted: Jan 26, 2023 2:14 PM CST
(CNN) -- The US Centers for Disease Control and Prevention is ironing out the "logistical and legal" aspects of testing wastewater from airplanes for coronavirus variants as it continues to explore such an infectious disease monitoring program.

The agency is still "figuring out how to operationalize this program," a person close to CDC discussions said, adding that there are "logistical and legal" hurdles that need to be sorted out before the program "would be operational."

Some of the agency's partners tell CNN that they are poised to help roll out this potential next frontier in the nation's Covid-19 surveillance effort.

Monitoring sewage for traces of coronavirus variants is a "validated" scientific process -- no longer in its pilot phase -- and airplanes are a logical next step, said Matt McKnight, general manager at Boston-based synthetic biology company Ginkgo Bioworks. Its Concentric by Ginkgo biosecurity and public health unit has been chosen to partner in the CDC's traveler-based genomic surveillance program to detect Covid-19 and flu variants among international travelers.

For now, the use of testing services to collect and analyze airplane wastewater for variants "is an active conversation between CDC, the White House and the airlines," McKnight said.

But the process of testing airplane wastewater itself is "validated methodology, and it is a program that can be run actively," he added. "The system is ready to go."

How wastewater monitoring works

Testing aircraft wastewater involves collecting sewage from individual passenger-carrying commercial airplanes.

"You can pull it off the airplane in under two minutes, quickly put it into a lab network, which we manage all of that," McKnight said.

Once those wastewater samples arrive at a diagnostic lab for testing, scientists scan them for traces of known or unknown viruses, such as emerging variants of SARS-CoV-2, the coronavirus that causes Covid-19. When samples test positive for the virus, scientists conduct genome sequencing to identify exactly which variant that virus is.

"Usually, sequencing takes about five to seven days," said Casandra Philipson, a researcher and program lead for Ginkgo Bioworks. Then, scientists may analyze their results and submit their findings to the CDC.

"We can do analysis really quickly," Philipson said, such as in a few days. "And then return results immediately."

Both McKnight and Philipson said that airplane wastewater surveillance not only can help with detecting emerging coronavirus and influenza variants -- serving as a "radar system" -- it can alert vaccine makers to which variants our Covid-19 shots might need to target each year.

Advisers to the US Food and Drug Administration are scheduled to meet this week to discuss Covid-19 vaccines becoming annual immunizations, similar to the seasonal flu vaccine.

That process could include streamlining the vaccine composition, immunization schedules and periodic updates of vaccines, according to meeting documents posted Monday. The FDA has said it expects to assess circulating strains of the coronavirus at least annually and decide in June which strains to select for the fall season, similar to the process of updating annual flu vaccines.

"If you give Moderna or Pfizer information early enough, they can make a vaccine really quickly, which we couldn't do at the beginning of the pandemic," McKnight said. "The big lesson learned is that you can think about all of these variants of viruses circulating around the world, and it's kind of like anything else we would have a radar system for, to detect what is out there so you can get an early warning."

A 'valuable component'

A report released last week by the National Academies of Sciences, Engineering and Medicine describes wastewater surveillance as a "valuable component" of infectious disease management and notes that wastewater surveillance at major US airports and ports of entry could help identify initial cases for pathogens from other regions among international travelers. The report was produced at the request of the CDC.

https://www.investorvillage.com/uploads/87669/files/Wastewater-testing.pdf

[trade2brich]

This thing is going to explode

[lettruthringout]

Two largest Ginkgo shareholders further up their holdings

https://www.investorvillage.com/smbd.asp?mb=20048&mn=10&pt=msg&mid=23856055

[lettruthringout]

Jason Kelly at World Economic Forum

https://www.onenewspage.com/video/20230120/15350947/Jason-Kelly-CEO-of-Ginkgo-Bioworks.htm

WORLD ECONOMIC FORUM ANNUAL MEETING
Biotech (R)evolution
January 18, 2023 16:15–17:00CET
As the biotech revolution continues to unfold, there is a landscape of potential for these technologies in medicine, food and materials.

What are the most investable technologies for industry deployment in the next decade?

Public Speakers
Magdalena Skipper
Editor-in-Chief, Nature

Jason Kelly
Chief Executive Officer, Ginkgo Bioworks

Joanna Shields
Chief Executive Officer, BenevolentAI

Mads Krogsgaard Thomsen
Chief Executive Officer, Novo Nordisk Foundation

K T Rama Rao
Minister of Information Technology, Industries, Municipal Administration and Urban Development, Government of Telangana

[lettruthringout]

In on LEAPS today

Mostly Jan '25 but some on Jan. '24. Wish the founders would quit selling.

WORLD ECONOMIC FORUM ANNUAL MEETING
Biotech (R)evolution
January 18, 2023 16:15–17:00CET
As the biotech revolution continues to unfold, there is a landscape of potential for these technologies in medicine, food and materials.

What are the most investable technologies for industry deployment in the next decade?

Public Speakers
Magdalena Skipper
Editor-in-Chief, Nature

Jason Kelly
Chief Executive Officer, Ginkgo Bioworks

Joanna Shields
Chief Executive Officer, BenevolentAI

Mads Krogsgaard Thomsen
Chief Executive Officer, Novo Nordisk Foundation

K T Rama Rao
Minister of Information Technology, Industries, Municipal Administration and Urban Development, Government of Telangana

[buyittradeit]

keeping a eye on it.

[Porterhouse10]

No

[buyittradeit]

sub dollar?

[20stockman20]

Ever see the movie MONEYBALL?
That is my strategy for playing the market.
Not trying to hit homers, looking for small but steady profits.

[20stockman20]

Sold gold stocks for a orofit, looking to roll profits _into DNA at $1.90

[20stockman20]

Way to go. Picked some shares of KGC, HL

[wiredawg]

I also bought a bit at current lows, averaged down quite a bit from my initials buys from year ago (Dec 2021). A gamble here, but I'm willing to stay-the-course and bottom fish for a few more shares and wait it out. Let's hope the new year brings DNA some decent upward movement.

https://www.marketscreener.com/quote/stock/GINKGO-BIOWORKS-HOLDINGS-127173269/news/Berenberg-Bank-Initiates-Coverage-on-Ginkgo-Bioworks-With-Buy-Rating-4-Price-Target-42427724/

[20stockman20]

Sold DNA moved into gold

[oregon 1]

DNA not looking good

[20stockman20]

Bought in at $1.85

[Porterhouse10]

Hence the Shorts crushing it, insider sells and not Buys doesn't help either, lots of folks stuck

[trade2brich]

ARK loaded the boat today!

[Porterhouse10]

ShIT got real there, kinda held, thx for the post. Cheers

[wiredawg]

Ginkgo Bioworks Launches $100 Million Common Stock Offering; Shares Down
Nov 16, 202210:12

DNA
-7.76%
Ginkgo Bioworks Holdings
DNA
said Wednesday it has launched a registered public offering of its class A common shares for about $100 million in gross proceeds.

BTIG, as the underwriter in offering, proposes to offer for sale the shares from time to time in one or more transactions. It has a 30-day overallotment option for up to an additional $15 million of the shares.

Ginkgo expects the offering to close around Friday and plans to use the net proceeds to offset the cash used to fund its acquisition of certain assets and liabilities of Bayer CropScience, among other uses.

The company's shares were down 8.8% in recent trading.

https://www.tradingview.com/news/mtnewswires.com:20221116:A2791520:0-ginkgo-bioworks-launches-100-million-common-stock-offering-shares-down/

[buyittradeit]

ikr. stopped out of this one.

[Porterhouse10]

Yikes

[buyittradeit]

Good sign

[Porterhouse10]

Theres a shot fired across the bow @3.00 $DNR

[buyittradeit]

Yes we need to see above 3.

[Porterhouse10]

Decent recovery here, need to see a $3 break for good $DNA 2,790 shares @$2.80 avg.

[buyittradeit]

Can not short it but I can trade options here thanks for the heads up

[Porterhouse10]

No wonder its tanking, CEO selling shares, doesnt bode well for sentiment on this

[buyittradeit]

i picked up a little.

[Porterhouse10]

200 more $2.58, 400 this week, we shall see $DNA markets are Wack

[Porterhouse10]

Ready for another 200

[buyittradeit]

Still under three? Hmmmmm may have to pick some up

[buyittradeit]

Nice size bids.......